Inactive Instrument

Pear Therapeutics, Inc.

PEAR

US7047231052

Biotechnology & Medical Research

Pear Therapeutics, Inc. Went Out of Business

May 23, 2024 at 09:30 am IST

Pear Therapeutics, Inc. went out of business as its plan of liquidation became effective on May 23, 2024.

Latest news about Pear Therapeutics, Inc.

Pear Therapeutics, Inc. Went Out of Business	23/05	CI
Combined Liquidation Plan and Disclosure Statement Approved for Pear Therapeutics, Inc.	08/05	CI
Disclosure Statement and Plan Approved on Interim Basis for Pear Therapeutics, Inc.	22/03	CI
Combined Liquidation Plan and Disclosure Statement Filed by Pear Therapeutics, Inc.	04/03	CI
Third Motion for Exclusivity Period Extension Approved For Pear Therapeutics, Inc.	12/02	CI
Second Motion for Exclusivity Period Extension Approved For Pear Therapeutics, Inc.	13/12	CI
First Motion for Exclusivity Period Extension Approved For Pear Therapeutics, Inc.	04/23/04	CI
First Motion for Exclusivity Period Extension Filed by Pear Therapeutics, Inc.	20/23/20	CI
Motion for Asset Sale Approved for Pear Therapeutics, Inc.	23/23/23	CI
Motion for Asset Sale Approved for Pear Therapeutics, Inc.	23/23/23	CI
Asset Purchase Agreement Filed by Pear Therapeutics, Inc.	21/23/21	CI
Asset Purchase Agreement Filed by Pear Therapeutics, Inc.	20/23/20	CI
Notice of Auction Resluts Filed by Pear Therapeutics, Inc.	19/23/19	CI
Bidding Procedure Approved for Pear Therapeutics, Inc.	28/23/28	CI
Pear Therapeutics, Inc.(OTCPK:PEAR.Q) dropped from S&P TMI Index	21/23/21	CI
Pear Therapeutics, Inc.(OTCPK:PEAR.Q) dropped from NASDAQ Composite Index	18/23/18	CI
Wall Street Set to Open Lower, March Retail Sales Fall More Than Expected	14/23/14	MT
US Equity Futures Mixed Ahead of Retail Sales, Industrial Production, Consumer Sentiment Reports	14/23/14	MT
Top Premarket Decliners	14/23/14	MT
Motion for Joint Administration Approved for Pear Therapeutics, Inc.	12/23/12	CI
Top Midday Decliners	10/23/10	MT
Pear Therapeutics Intends to Pursue a Sale of the Business or Assets	08/23/08	CI
Pear Therapeutics, Inc. Announces Executive Changes	07/23/07	CI
Pear Therapeutics, Inc. Announces Resignation of Corey Mccann, M.D., Ph.D. as Chief Executive Officer	07/23/07	CI
Motion for Joint Administration Filed by Pear Therapeutics, Inc.	07/23/07	CI

Pear Therapeutics, Inc. is a commercial-stage healthcare company. The Company is engaged in developing a new class of software-based medicines that is referred to as prescription digital therapeutics (PDTs), which use software to treat diseases directly. Its products include reSET and reSET-O. The Company's reSET product is indicated for the treatment of substance use disorder (SUD) as a monotherapy. Its reSET-O product is developed for the treatment of opioid use disorder (OUD) in combination with buprenorphine. The Companyâs pipeline consists of product candidates in psychiatry, neurology, and outside-of-central nervous system therapeutic areas. The Company has built a portfolio of PDT product candidates that is primarily focused on psychiatric conditions.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+34.14%	51.12B
IQVIA HOLDINGS INC.	-6.54%	39.4B
LONZA GROUP AG	+34.92%	38.48B
ICON PUBLIC LIMITED COMPANY	+12.62%	26.36B
CELLTRION, INC.	-12.11%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-13.43%	20.96B
UNITED THERAPEUTICS CORPORATION	+43.73%	14.02B
MEDPACE HOLDINGS, INC.	+31.81%	12.49B
BIO-TECHNE CORPORATION	-4.54%	11.61B

Other Biotechnology & Medical Research